Current progress in diagnostics, therapeutics, and vaccines for African swine fever virus

African Swine Fever Virus (ASFV) is a highly contagious viral disease that affects domestic and wild pigs. Due to its high mortality rate and rapid spread, it poses a significant threat to the global swine industry. There is currently no effective treatment for ASFV, and control strategies rely on early detection and culling of infected animals. Therefore, developing efficient diagnostics, therapeutics, and vaccines for ASFV is crucial for preventing its spread and minimizing the economic losses associated with outbreaks. In recent years, significant progress has been made in developing diagnostic tools for ASFV, including serological, molecular, and cell-based assays. Therapeutic interventions for ASFV are limited, with no approved treatments currently available. However, recent studies have explored the potential of antiviral drugs and immunomodulators as potential therapies for ASFV. Meanwhile, vaccines have been developed using different platforms, including live attenuated viruses, subunit vaccines, and viral vectors. Some of these vaccines have shown promising results in inducing both humoral and cell-mediated immune responses, but challenges remain in terms of vaccine efficacy. Therefore, significant progress has been made in developing diagnostics, therapeutics, and vaccines for ASFV, but much work remains to be done. Further research is needed to improve the efficacy and safety of current interventions and to develop new tools for controlling ASFV globally.